HHS expands U.S.-based pharmaceutical manufacturing to get drugs to hospitals faster

May 21, 2020 / Susan Morse, Managing Editor

The Department of Health and Human Services will work with a team of private industry partners led by Phlow Corporation of Richmond, Virginia, to expand pharmaceutical manufacturing in the United States to provide medicines needed during COVID-19 and future public health emergencies.

The U.S. government and Phlow are developing a prioritized list of active pharmaceutical ingredients and finished medicines critically needed by healthcare systems.

The Phlow-led team will provide immediate, U.S.-based capacity to produce the active pharmaceutical ingredients and the chemical compounds for ingredients needed to help alleviate or prevent drug shortages.

The drug ingredients will be manufactured at facilities in the United States, including a new facility to be built in Virginia.


Print Friendly, PDF & Email

Chris J. Stewart

Chris currently serves as Chief Executive Officer of Surgio Health as well as Chief Operating Officer at Ortho Spine Partners. Prior to that, he was the assistant vice president and business unit leader of Medical Device Management for HealthTrust Purchasing Group (HPG).

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button